Dual bNAb maintains viral suppression for median 21 weeks off-ART


In the first presentation in a session at R4P2018 looking at using bNAbs for prevention, Pilar Mendoza from the Rockefeller University presented results on the impact of a combination of two antibodies in HIV positive people on ART who then took an analytic treatment interruption (ATI).

The two bNAbs, 3BNC117 and 10-1074, target non-overlapping epitopes and provide broader coverage.  All 11 participants were initially screened for sensitivity to both antibodies (there was an approximate 50% rate of failing screening) and were on effective ART.